A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease

NCT01685437 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
189
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Endo Pharmaceuticals